Vanta Bioscience Ltd Financials
Company Logo

Vanta Bioscience Ltd Financial Statement

Vanta Bioscience Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2023
Revenue2.37
Operating Expense2.88
Net Profit-1.22
Net Profit Margin-51.48
Earning Per ShareTBA
EBIDTA-0.51
Effective Tax RateTBA

Vanta Bioscience Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual8.56
Operating Expenses Annual4.91
Operating Profit Annual3.70
Interest Annual2.42
Depreciation1.24
Net Profit Annual0.05
Tax Annual-0.01

Vanta Bioscience Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.07
Cash Flow from Operations4.55
Cash Flow from Investing-1.67
Cash Flow from Financing-2.81
Cash Flow at the End0.14

Vanta Bioscience Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)42.76
PBIT Margin (%)28.27
PBT Margin (%)16.59
Net PROFIT Margin (%)0.58
Return On Networth / Equity (%)0.05
Return On Networth /Employed (%)5.24
Return On Assets (%)0.11
Total Debt / Equity (X)1.29
Asset Turnover Ratio (%)0.19

Vanta Bioscience Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual37.87
Total Current Assets Annual12.03
Non Current Assets Annual40.88
Total Shareholders Funds Annual19.79
Total Assets Annual52.91

Vanta Bioscience Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

0.00

Surprise

0.00%

Dec 2022

EPS beaten by 0.00%

Dec 2021

EPS beaten by 0.00%

Get Your FAQs Right

As of Dec 5, 2024, Vanta Bioscience Ltd has a market capitalization of 40.40 Cr. Value Research classifies it as a Micro-Cap company.
No, Vanta Bioscience Ltd is not debt-free with a debt-to-equity ratio of 1.28.
In FY 2023 , Vanta Bioscience Ltd recorded a total revenue of approximately 8.56 Cr marking a significant milestone in the company's financial performance.
Vanta Bioscience Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and -0.0% annually, respectively..
Vanta Bioscience Ltd's current PE ratio is 808.00.
Vanta Bioscience Ltd's ROCE averaged 2.7% from the FY ending March 2022 to 2024, with a median of 5.0%. It peaked at 5.5% in March 2024, reflecting strong capital efficiency over the period..
Vanta Bioscience Ltd's latest EBIT is Rs. 2.46 Cr, surpassing the average EBIT of Rs. 1.20 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions